Bio-Path Holdings Company Profile (NASDAQ:BPTH)

About Bio-Path Holdings (NASDAQ:BPTH)

Bio-Path Holdings logoBio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BPTH
  • CUSIP: N/A
  • Web: www.biopathholdings.com
Capitalization:
  • Market Cap: $45.03 million
  • Outstanding Shares: 100,056,000
Average Prices:
  • 50 Day Moving Avg: $0.36
  • 200 Day Moving Avg: $0.44
  • 52 Week Range: $0.25 - $1.50
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.09
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $13,000.00
  • Price / Sales: 3,463.48
  • Book Value: $0.09 per share
  • Price / Book: 5.00
Profitability:
  • EBITDA: ($8,690,000.00)
  • Return on Equity: -56.53%
  • Return on Assets: -43.24%
Debt:
  • Current Ratio: 13.65%
  • Quick Ratio: 13.65%
Misc:
  • Average Volume: 467,222 shs.
  • Beta: 3.13
  • Short Ratio: 5.25
 

Frequently Asked Questions for Bio-Path Holdings (NASDAQ:BPTH)

What is Bio-Path Holdings' stock symbol?

Bio-Path Holdings trades on the NASDAQ under the ticker symbol "BPTH."

How were Bio-Path Holdings' earnings last quarter?

Bio-Path Holdings, Inc. (NASDAQ:BPTH) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by $0.01. View Bio-Path Holdings' Earnings History.

When will Bio-Path Holdings make its next earnings announcement?

Bio-Path Holdings is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Bio-Path Holdings.

Where is Bio-Path Holdings' stock going? Where will Bio-Path Holdings' stock price be in 2017?

2 equities research analysts have issued 12-month price targets for Bio-Path Holdings' stock. Their forecasts range from $2.00 to $5.00. On average, they anticipate Bio-Path Holdings' share price to reach $3.50 in the next year. View Analyst Ratings for Bio-Path Holdings.

Who are some of Bio-Path Holdings' key competitors?

Who are Bio-Path Holdings' key executives?

Bio-Path Holdings' management team includes the folowing people:

  • Peter Henry Nielsen, Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Treasurer
  • Ulrich W. Mueller Ph.D., Secretary
  • Douglas P. Morris, Director
  • Heath W. Cleaver CPA, Independent Director
  • Mark P. Colonnese, Independent Director

How do I buy Bio-Path Holdings stock?

Shares of Bio-Path Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Path Holdings' stock price today?

One share of Bio-Path Holdings stock can currently be purchased for approximately $0.45.


MarketBeat Community Rating for Bio-Path Holdings (NASDAQ BPTH)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  118 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  184
MarketBeat's community ratings are surveys of what our community members think about Bio-Path Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Bio-Path Holdings (NASDAQ:BPTH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.50 (677.78% upside)
Consensus Price Target History for Bio-Path Holdings (NASDAQ:BPTH)
Price Target History for Bio-Path Holdings (NASDAQ:BPTH)
Analysts' Ratings History for Bio-Path Holdings (NASDAQ:BPTH)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/11/2017HC WainwrightSet Price TargetBuy$5.00HighView Rating Details
4/5/2017Maxim GroupSet Price TargetBuy$2.00HighView Rating Details
8/11/2016Rodman & RenshawSet Price TargetBuy$5.00N/AView Rating Details
(Data available from 10/17/2015 forward)

Earnings

Earnings History for Bio-Path Holdings (NASDAQ:BPTH)
Earnings by Quarter for Bio-Path Holdings (NASDAQ:BPTH)
Earnings History by Quarter for Bio-Path Holdings (NASDAQ BPTH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($0.02)N/AView Earnings Details
8/10/2017Q2 2017($0.02)($0.03)ViewListenView Earnings Details
5/11/2017Q1 2017($0.02)($0.01)ViewN/AView Earnings Details
3/15/201712/31/2016($0.03)($0.01)$0.01 millionViewListenView Earnings Details
11/9/2016Q316($0.02)($0.02)$2.50 millionViewListenView Earnings Details
8/9/2016Q2($0.02)($0.02)ViewN/AView Earnings Details
5/11/2016Q1($0.01)($0.02)$2.33 millionViewListenView Earnings Details
3/16/2016Q4($0.01)($0.02)$1.46 millionViewN/AView Earnings Details
11/10/2015Q315($0.02)ViewN/AView Earnings Details
8/11/2015Q2 2015($0.03)($0.01)ViewN/AView Earnings Details
3/17/2015Q4 2014$0.01($0.02)ViewN/AView Earnings Details
11/17/2014Q3 2014($0.01)($0.01)ViewN/AView Earnings Details
8/18/2014Q214($0.01)($0.01)ViewN/AView Earnings Details
4/2/2014$0.01$0.01ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bio-Path Holdings (NASDAQ:BPTH)
Current Year EPS Consensus Estimate: $-0.08 EPS
Next Year EPS Consensus Estimate: $-0.11 EPS

Dividends

Dividend History for Bio-Path Holdings (NASDAQ:BPTH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Bio-Path Holdings (NASDAQ:BPTH)
Insider Ownership Percentage: 12.54%
Institutional Ownership Percentage: 15.16%
Insider Trades by Quarter for Bio-Path Holdings (NASDAQ:BPTH)
Institutional Ownership by Quarter for Bio-Path Holdings (NASDAQ:BPTH)
Insider Trades by Quarter for Bio-Path Holdings (NASDAQ:BPTH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/13/2015Michael J GarrisonDirectorBuy7,343$1.22$8,958.46View SEC Filing  
7/9/2015Michael J GarrisonDirectorBuy8,724$1.17$10,207.08View SEC Filing  
7/8/2015Michael J GarrisonDirectorBuy60,000$1.19$71,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Bio-Path Holdings (NASDAQ:BPTH)
Latest Headlines for Bio-Path Holdings (NASDAQ:BPTH)
Source:
DateHeadline
finance.yahoo.com logoIs It Time To Buy Bio-Path Holdings Inc (BPTH)?
finance.yahoo.com - October 11 at 6:11 PM
americanbankingnews.com logoBio-Path Holdings, Inc. (BPTH) Expected to Post Earnings of -$0.02 Per Share
www.americanbankingnews.com - October 11 at 12:20 PM
seekingalpha.com logoBio-Path (BPTH) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 5:52 PM
globenewswire.com logoBio-Path Holdings to Present at the Rodman & Renshaw Annual Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 5 at 11:19 PM
finance.yahoo.com logoBio-Path Holdings to Present at the Rodman & Renshaw Annual Healthcare Conference
finance.yahoo.com - September 5 at 6:17 PM
americanbankingnews.com logo-$0.02 EPS Expected for Bio-Path Holdings, Inc. (BPTH) This Quarter
www.americanbankingnews.com - September 4 at 4:28 AM
americanbankingnews.com logoBio-Path Holdings, Inc. (NASDAQ:BPTH) PT Set at $5.00 by HC Wainwright
www.americanbankingnews.com - August 13 at 3:32 PM
americanbankingnews.com logoBio-Path Holdings, Inc. (NASDAQ:BPTH) Releases Earnings Results
www.americanbankingnews.com - August 11 at 2:34 PM
seekingalpha.com logoBio-Path Holdings' (BPTH) CEO Peter Nielsen on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 10 at 5:50 PM
finance.yahoo.com logoBio-Path reports 2Q loss
finance.yahoo.com - August 10 at 5:50 PM
globenewswire.com logoBio-Path Holdings to Announce Second Quarter 2017 Financial Results on August 10, 2017 - GlobeNewswire (press release)
globenewswire.com - August 4 at 4:58 PM
finance.yahoo.com logoBio-Path Holdings to Announce Second Quarter 2017 Financial Results on August 10, 2017
finance.yahoo.com - August 3 at 6:08 PM
americanbankingnews.com logoBio-Path Holdings, Inc. (NASDAQ:BPTH) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:17 AM
finance.yahoo.com logoBio-Path Holdings Receives Notice of Allowance for Key U.S. Composition of Matter Patent
finance.yahoo.com - July 31 at 4:44 PM
globenewswire.com logoBio-Path Holdings Receives Notice of Allowance for Key US Composition of Matter Patent - GlobeNewswire (press release)
globenewswire.com - July 20 at 11:21 PM
americanbankingnews.com logoBio-Path Holdings, Inc. (NASDAQ:BPTH) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - July 20 at 8:42 AM
streetinsider.com logoBio-Path Holdings (BPTH) Granted Allowance for Key US Composition of Matter Patent for DNAbilize by USPTO - StreetInsider.com
www.streetinsider.com - July 19 at 5:52 PM
nasdaq.com logoBio-Path Holdings Appoints Mark Colonnese to its Board of Directors - Nasdaq
www.nasdaq.com - July 17 at 5:04 PM
finance.yahoo.com logoBio-Path Holdings Appoints Mark Colonnese to its Board of Directors
finance.yahoo.com - July 17 at 12:23 PM
baystreet.ca logoStonegate Capital Partners Initiates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) - Baystreet.ca
www.baystreet.ca - June 30 at 4:49 PM
seekingalpha.com logoBio-Path Holdings' (BPTH) CEO Peter Nielsen on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 4:36 PM
seekingalpha.com logoBio-Path Holdings (BPTH) Presents At Oppenheimer 27th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 23 at 1:49 AM
biz.yahoo.com logoBio Path Holdings Inc Earnings Call scheduled for 8:30 am ET today
biz.yahoo.com - March 15 at 9:21 PM
us.rd.yahoo.com logoBio-Path Holdings Reports Full Year 2016 Financial Results
us.rd.yahoo.com - March 15 at 4:20 PM
biz.yahoo.com logoBIO-PATH HOLDINGS INC Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 15 at 4:20 PM
biz.yahoo.com logoBIO-PATH HOLDINGS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Fi
us.rd.yahoo.com - March 15 at 4:20 PM
us.rd.yahoo.com logoBio-Path Holdings to Present Data at the 2017 AACR Annual Meeting
us.rd.yahoo.com - March 10 at 4:57 PM
biz.yahoo.com logoBIO-PATH HOLDINGS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand
biz.yahoo.com - March 8 at 4:46 PM
globenewswire.com logoBio-Path Holdings to Present at the 19th Annual BIO CEO & Investor Conference - GlobeNewswire (press release)
globenewswire.com - February 9 at 9:14 PM
biz.yahoo.com logoBIO-PATH HOLDINGS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosu
biz.yahoo.com - December 16 at 4:21 PM
streetinsider.com logoBio-Path Holdings (BPTH) Announces Presentation of BP1001 Data as CML Treatment at ASH 2016
www.streetinsider.com - December 7 at 2:22 AM
us.rd.yahoo.com logoBio-Path Holdings Presents Clinical Data Evaluating BP1001 as a Treatment for Chronic Myelogenous Leukemia at the 58th Annual American Society of Hematology Annual Meeting
us.rd.yahoo.com - December 6 at 4:18 PM
us.rd.yahoo.com logo7:01 am Bio-Path reviews BP1001 data as a treatment for chronic myelogenous leukemia at ASH 2016; results demonstrate BP1001 decreased the proliferation of Gleevec (imatinib)-resistant CML cells in a dose-dependent manner
us.rd.yahoo.com - December 6 at 4:18 PM
biz.yahoo.com logoBIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - December 6 at 4:18 PM
streetinsider.com logoBio-Path Holdings (BPTH) Announces Presentation of BP1001 Data as CML Treatment at ASH 2016 - StreetInsider.com
www.streetinsider.com - December 6 at 12:14 PM

Social

Chart

Bio-Path Holdings (BPTH) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.